KEGG   DRUG: Inebilizumab
Entry
D11757                      Drug                                   
Name
Inebilizumab (USAN/INN);
Inebilizumab (genetical recombination) (JAN);
Inebilizumab-cdon;
Uplizna (TN)
Product
Formula
C6504H10080N1732O2044S44
Exact mass
146560.5771
Mol weight
146650.866
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SSWMNWVRQA PGKGLEWVGR IYPGDGDTNY
NVKFKGRFTI SRDDSKNSLY LQMNSLKTED TAVYYCARSG FITTVRDFDY WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
EIVLTQSPDF QSVTPKEKVT ITCRASESVD TFGISFMNWF QQKPDQSPKL LIHEASNQGS
GVPSRFSGSG SGTDFTLTIN SLEAEDAATY YCQQSKEVPF TFGGGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(Disulfide bridge: H22-H96, H148-H204, H224-L224, H230-H'230, H265-H325, H371-H429, LH'22-H'96, H'148-H'204, H'224-L'218 H'148-H'204, G'265-H'325, H'371-H'429, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  Type
Peptide
Remark
Therapeutic category: 6399
ATC code: L04AG10
Product: D11757<JP/US>
Efficacy
Antineoplastic, Anti-CD19 antibody
  Disease
Neuromyelitis optica spectrum disorder (AQP4 antibody positive) [DS:H01491]
  Type
Monoclonal antibody
Comment
Treatment of cancer, systemic sclerosis, and multiple sclerosis
Target
CD19 [HSA:930] [KO:K06465]
  Pathway
hsa04151  PI3K-Akt signaling pathway
hsa04640  Hematopoietic cell lineage
hsa04662  B cell receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AG Monoclonal antibodies
     L04AG10 Inebilizumab
      D11757  Inebilizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Ophthalmic Agents
  Ophthalmic Agents, Other
   Inebilizumab
    D11757  Inebilizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D11757  Inebilizumab (USAN/INN); Inebilizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD19
     D11757  Inebilizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11757
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11757
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11757
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11757
Other DBs
CAS: 1299440-37-1
PubChem: 405226623
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system